Abstract
Purpose
To evaluate the immediate and short-term effects of intravitreal injection of 1.25 mg/0.05 ml of bevacizumab on intraocular pressure related to different ocular axial lengths.
Design
A prospective case series of consecutive patients referred to the Department of Ophthalmology, San Pietro-Fatebenefratelli Hospital, from September 2011 through January 2011.
Methods
Twenty-five patients (10 men and 15 women, mean age 70.2 ± 8.98 years) scheduled for intravitreal injection of bevacizumab for the treatment of neovascular age-related macular degeneration were enrolled in this study. Axial length was measured preoperatively using IOLMaster. Intraocular pressure was measured before injection, after 1 min and after 15 min using Tono-Pen XL tonometry.
Results
The mean intraocular pressure change following the intravitreal bevacizumab injection was 21.92 ± 6.95 mmHg after 1 min and 6.24 ± 3.77 mmHg after 15 min. The mean axial length of the examined eyes was 23.2 ± 1.06 mm. A good correlation was observed between the axial length and intraocular pressure rise after both 1 (R 2 = 0.752, p < 0.001) and 15 min (R 2 = 0.559, p < 0.001).
Conclusions
Patients undergoing intravitreal injection of 0.05 ml of bevacizumab can be exposed to intraocular pressure increases correlated to ocular axial length.
Similar content being viewed by others
References
Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.
Rl Avery, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–72.
Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularisation in pathologic myopia. Retina. 2006;26:1093–4.
Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85:777–81.
Frenkel REP, Mani L, Toler AR, Frenkel MPC. Intraocular pressure effects of Pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034–5.
Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23:181–5.
Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930–4.
Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol. 2009;24:100–5.
Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27:1044–7.
Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42:807–11.
Utman SA, Dhillon B. Comment on: changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2008;28:667.
Tsui YP, Chiang CC, Tsai YY. Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol. 2008;43:239.
Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arc Ophthalmol. 2010;128:1523–7.
Kim KS, Jee D. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol. 2011;55:632–7.
Ueda T, Nawa Y, Hara Y. Relationship between the retinal thickness of the macula and the difference in axial length. Graefes Arch Clin Exp Ophthalmol. 2006;244:498–501.
Kojima T, Tamaoki A, Yoshida N, Kaga T, Suto C, Ichikawa K. Evaluation of axial length measurement of the eye using partial coherence interferometry and ultrasound in cases of macular disease. Ophthalmology. 2010;117:1750–4.
Guidelines for performing intravitreal therapy. The Royal Australian and New Zealand College of Ophthalmologists. 2006.
Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusin P. Short-term effect of intravitreal injection of ranibizumab (lucentis) on intraocular pressure. J Glaucoma. 2009;18:658–61.
Boon CJF, Crama N, Klevering BJ, van Kuijk FJ, Hoyng CB. Reflux after intravitreal injection of bevacizumab. Ophthalmology. 2008;115:1270.
Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005;45:409–14.
Pallikaris IG, Kymionis GD, Ginis SH, Kounis GA, Christodoulakis E, Tsilimbaris MK. Ocular rigidity in patients with age related macular degeneration. Am J Ophthalmol. 2006;141:611–5.
Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol. 2011;89:138–42.
Ethical standard
The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local Ethics Committee. Each patient signed an informed consent before enrollment.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Cacciamani, A., Oddone, F., Parravano, M. et al. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 57, 63–67 (2013). https://doi.org/10.1007/s10384-012-0194-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-012-0194-8